Read more

March 05, 2023
4 min watch
Save

Researchers use CAR-T gel to kill leftover cancer cells after surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Local administration of chimeric antigen receptor T cells via a fibrin-based gel effectively eliminated leftover cancer cells after incomplete surgical resection, study results published in Science Advances showed.

Researchers evaluated the safety and efficacy of a mesothelin-targeted CAR-T construct and delivery method against pancreatic ductal adenocarcinoma and triple-negative breast cancer models.

The findings suggest the CAR-T-infused gel can prevent tumor recurrence typically caused by residual cancer cells after surgery and do so without wound-healing complications, according to investigators.

Healio spoke with Ugur Uslu, MD, dermatologist and postdoctoral fellow for cancer immunotherapy in the laboratory of Carl H. June, MD, at Perelman School of Medicine at University of Pennsylvania, about the study results and his group’s plans for a first-in-human clinical trial.